| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5837284 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US6635284 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US7431944 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US6228398 | SANDOZ | Multiparticulate modified release composition |
Nov, 2019
(4 years ago) | |
Ritalin La is owned by Sandoz.
Ritalin La contains Methylphenidate Hydrochloride.
Ritalin La has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Ritalin La are:
- US5837284
- US6635284
- US7431944
- US6228398
Ritalin La was authorised for market use on 10 April, 2004.
Ritalin La is available in capsule, extended release;oral dosage forms.
Ritalin La can be used as treatment of attention deficit hyperactivity disorder using a dosage form which provides once-daily oral administration of a phenidate drug, treatment of attention deficit hyperactivity disorder using methylphenidate bi-modal release profile extended-release capsules.
The generics of Ritalin La are possible to be released after 01 November, 2019.
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 April, 2004
Treatment: Treatment of attention deficit hyperactivity disorder using a dosage form which provides once-daily oral administration of a phenidate drug; Treatment of attention deficit hyperactivity disorder using...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RITALIN LA family patents
